Introduction
Acute lymphoblastic leukemia (ALL) is a neoplasm characterized by malignant expansion of immature lymphoblasts committed to the T-cell lineage (T-ALL) or the Bcell lineage (B-ALL). T-ALL accounts for approximately 10-15% of adult and 25% of childhood ALL cases. [1] [2] [3] Mortality rates of T-ALL patients have significantly decreased over the last twenty years due to advances in the treatment of this aggressive subset of ALL. 4 T-ALL and B-ALL patients have approximately the same five-year overall survival rates (FSR), 35-40% in adults and 75-85% for children and adolescents. 1 However, T-ALL is a more aggressive disease with a poorer clinical outcome than B-ALL. T-ALL patients have a higher percentage of induction failure, rate of relapse and invasion into the central nervous system compared to B-ALL patients. 5 In addition, a subset of T-ALL patients (20-25%) is refractory to initial treatment or relapse after a short remission period due to drug resistance.
A number of oncogenes and tumor suppressors have been implicated in T-ALL etiology. Expression of the protoconcogenes c-Myc, Notch, LMO1/2, LYL1, TAL1/2, HOX11, and HOX11L2 in murine hematopoietic progenitors leads to development of a heterogeneous population of T-ALL subtypes. Loss of the tumor suppressors p53 or
Ikaros also results in the development of lymphoma in knockout mouse models. [6] [7] [8] Human tumors are characterized into subtypes based on the expression of LMO1/2, LYL1, TAL1/2, HOX11, and HOX11L2. Interestingly, activating Notch1 mutations have been found in all subtypes of T-ALL. 9 We have suggested that Notch activation is a dominant event necessary for leukemogenesis even in the presence of other T-ALLassociated genes. 10 It is clear that activated Notch (Notch
IC ) is capable of inducing
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From cellular transformation and plays a central role in T-ALL progression. 9, [11] [12] [13] [14] [15] [16] Numerous Notch target genes have been identified, including the Hes and Hey family of transcriptional repressors, cyclin D1 and c-Myc. 9 ,17-21 Both Notch and c-Myc regulate cell-cycle progression by inducing expression of cyclins and reducing p27 expression.
17,18,20,22-25 However, unlike most oncogenes, including c-Myc, Notch is capable of inhibiting p53-mediated apoptosis. 13 Specifically, it was demonstrated that the p53 pathway is intact in a Notch IC -induced T-ALL tumor model; when Notch IC expression is extinguished the p53 pathway is activated leading to tumor regression. 13 A recent publication demonstrates that Notch and c-Myc-induced gene expression profiles are broadly overlapping in leukemia cells, as determined by microarray analysis, including multiple genes regulating cell cycle progression, protein biosynthesis and metabolism. 26 These data suggest that the c-Myc and Notch oncogenes may be able to compensate for each other in maintaining tumors since they appear to have similar functions and indicate that c-Myc may be the major downstream mediator of Notch function.
We sought to address the issue of oncogenic compensation by using inducible mouse model systems and forming tumors by expressing T-ALL-inducing levels of both 
Materials and Methods

Bone Marrow Reconstitutions
All animal procedures were approved by the Wistar Institute Animal Care and Use Committee. In order to generate tumors, Top-Notch or Tet-o-Myc mice were injected intraperitoneally with 300 µl of 100 µg/ml 5'-fluorouracil (5'-FU). Five days post 5'-FU injection bone marrow was collected. Mice were euthanized by CO 2 asphyxiation and the long bones of the leg (femur and tibia) were removed from the animal. Bone marrow was then flushed out into a tissue culture dish using phosphate buffered saline (PBS).
Bone marrow cells were pelleted at 311 x g and then red blood cells (RBC) were lysed using a hemolysis buffer (154 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM EDTA). Cells were pelleted and resuspended in RPMI (10% FBS, Penicillan/Streptamycin) with 100 ng/ml of SCF, IL-6 and IL-3 at a concentration of 2.0 x 10 6 cells/ml and cultured overnight at 37°C in a humidified atmosphere with 5% CO 2 . The next day, bone marrow cells were pelleted at 311 x g, resuspended in PBS and counted. Cells were resuspended at a concentration of 2 x 10 6 cells/ml, and 1 x 10 6 cells (500 µl) were then infected in culture using 1 ml of viral supernatant containing packaged retroviral vectors (MIT-GFP, MIT-cMyc or MIT-Notch IC ) at 1,950 x g for 2 h at room temperature. Lethally irradiated recipient mice (two doses of 550 rads from a sealed Cs-source irradiator with a 4 h relaxation period in between) were then reconstituted with 1.0 x 10 6 bone marrow derived cells by tail vein injection. Mice were then monitored for onset of disease.
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Mouse Tumor Regressions
Tumor cells were transplanted into syngenic mice in order to maintain live tumor tissue and to obtain multiple mice with the same primary tumor tissue for time point regression studies. Single cell suspensions were generated from spleen or lymph nodes from the primary tumor source. Tissue was added to a culture dish containing sterile PBS.
Single cell suspensions were generated under sterile conditions. Tissue was crushed to release cells and PBS containing cells was then filtered through a 0.45 µM cell strainer to remove contaminating tissue and pelleted at 311 x g. Red blood cells (RBC) were lysed using hemolysis buffer, pelleted, washed with PBS, and resuspended in PBS. Single cells
(1 x 10 6 ) were injected into recipient host animals via intravenous (tail vein) injection.
Mice were monitored for signs of disease. When mice were moribund (ie. enlarged spleen as evidenced by palpation, visibly enlarged lymph nodes (as shown in Figure 1D ), difficulty breathing and slow movement and response to stimulation), Doxycycline (Dox; 100 mg/ml) was administered into the drinking water.
Plasmids
The MIT vector was derived from the MIG-RX vector, which is a modification of Both the Top-Notch and Tet-o-Myc models have been described previously. 13, 30 In both models, when the Eµ-SRα expression driver is used to induce transgene expression, mice develop a characteristic T-ALL-like disease. 13, 16, 30 extinguished, tumors regressed due to p53-mediated apoptosis. 13 In addition, when these mice were crossed onto a p53 +/-background there was no acceleration in tumorigenesis and tumors did not exhibit LOH at the p53 locus, demonstrating that there is no pressure to mutate p53 in Notch induced tumors. Taken together these data reveal a model in which Notch drives T-ALL development by inducing sustainable cell cycle progression and inhibition of p53-mediated apoptosis.
10,13
The requirement for inactivating p53 pathway mutations in c-Myc-induced tumorigenesis has been well documented. 35, 36 Greater than 50% of Eµ-myc B-cell lymphomas harbor mutations that inactivate the p53 pathway and ARF +/-/Eµ-myc mice display LOH at the wild-type ARF allele in 80% of lymphomas. 35 We show herein that in Therefore, we propose that the advantage Notch provides to c-Myc-induced tumors is the ability to suppress p53-mediated apoptosis and relieve the requirement to obtain a p53 pathway mutation during tumor initiation and progression. These data indicate that the suppression of p53-mediated apoptosis in T-ALL is Notch-dependent and that c-Myc cannot rescue this function. Therefore, we propose that Notch exerts oncogenic dominance over Myc due to the fact that Notch can suppress p53-mediated apoptosis.
In contrast to the results reported here, a recent report presented evidence that cMyc can maintain some Notch-dependent T-ALL cell lines when Notch activity is inhibited using a gamma-secretase inhibitor (GSI). 25 In this study 3 out of 6 cell lines 
39,40
However, a high rate of p53 mutations was found in human T-ALL cells lines. 38 In addition, most human T-ALL cell lines have been established from relapsed tumors, which have a greater rate of p53 mutations (7-28%) than primary tumors. [39] [40] [41] Therefore, the increased rate of p53 mutations in human cell lines provides at least one mechanism that addresses why c-Myc is able to rescue some of the Notch-dependent T-ALL cell , but it has been demonstrated that loss of PTEN alone is not sufficient to maintain tumors when Notch activation is inhibited in a mouse model of T-ALL. 43 These data, along with our data, prove that mutations that induce cell cycle and inhibit p53- The analogy that tumors are like a house of cards is frequently used with the intention of expressing the concept that if one card is removed the "house" (or tumor) will fall. In other words, tumors are like a house of cards and that targeting specific oncogenes will result in effective treatment. However, we demonstrate here that just as in the house of cards analogy, loss of some but not all cards will collapse the "house".
Therefore, in order to make a particular "house" collapse on itself one must choose the "critical cards".
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